Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Other Stockholders Equity: €1,603 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:GU5 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd FRA:GU5
75 GF Score
Price €1.71
GF Value €2.39
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Other Stockholders Equity?

Guangzhou Baiyunshan Pharmaceutical Holdings Co FRA:GU5 +1.18% 75 Other Stockholders Equity is €1,603 Mil as of Mar. 2026. GuruFocus rates FRA:GU5 with a GF Score™ of 75/100 and a GF Value™ of €2.39 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Guangzhou Baiyunshan Pharmaceutical Holdings Co's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €1,603 Mil.

Guangzhou Baiyunshan Pharmaceutical Holdings Co's quarterly Other Stockholders Equity declined from Sep. 2025 (€1,490 Mil) to Dec. 2025 (€426 Mil) but then increased from Dec. 2025 (€426 Mil) to Mar. 2026 (€1,603 Mil).

Guangzhou Baiyunshan Pharmaceutical Holdings Co's annual Other Stockholders Equity increased from Dec. 2023 (€422 Mil) to Dec. 2024 (€447 Mil) but then declined from Dec. 2024 (€447 Mil) to Dec. 2025 (€426 Mil).

Guangzhou Baiyunshan Pharmaceutical Holdings Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Guangzhou Baiyunshan Pharmaceutical Holdings Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Other Stockholders Equity Chart

Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 389.04 423.67 422.00 446.91 426.06

Guangzhou Baiyunshan Pharmaceutical Holdings Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,589.44 410.27 1,489.76 426.06 1,602.61
FRA:GU5
75GF Score
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd FRA:GU5
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guangzhou Baiyunshan Pharmaceutical Holdings Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €1,603 Mil mean?
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) has a Other Stockholders Equity of €1,603 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's Other Stockholders Equity too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Other Stockholders Equity is €1,603 Mil. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's Other Stockholders Equity compare to MCK and CAH?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's Other Stockholders Equity of €1,603 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Distribution company?
A good Other Stockholders Equity depends on the Medical Distribution industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Other Stockholders Equity is €1,603 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.39, compared to a current price of €1.71 — trading 28.5% below its estimated fair value. The current Other Stockholders Equity is €1,603 Mil. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5), the current Other Stockholders Equity is €1,603 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Overvalued in 2026?

Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued. The current stock price of €1.71 is trading 28.5% below its estimated GF Value™ of €2.39. GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Modestly Undervalued.

Key valuation signals for FRA:GU5:

  • Other Stockholders Equity: €1,603 Mil
  • GF Value™: €2.39 vs. price of €1.71 (28.5% below fair value)
  • GF Score™: 75/100 with 6 warning signs

No single metric tells the full story. See the FRA:GU5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Business Description

Other Exchanges 00874:Hong Kong600332:China
Address 45 Sha Mian North Street, Liwan District, Guangdong Province, Guangzhou, CHN, 510130
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
75GF Score

Get the complete analysis for FRA:GU5

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.71
Price
€2.39
GF Value